Heart Failure Clinical Trial
— IVORYOfficial title:
Ingenio Device Algorithm Study
Verified date | March 2024 |
Source | Boston Scientific Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the IVORY Study is to gather data to support global submissions/approvals for some models of the Ingenio device family.
Status | Completed |
Enrollment | 139 |
Est. completion date | April 2013 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects who are willing and capable of providing informed consent to undergo a device implant and to participate in all testing associated with this clinical study; - Subjects whose age is 18 or above, or of legal age to give informed consent specific to national law; - Subjects indicated for a dual chamber pacemaker or a CRT-P device according to class I or class II indications of the standard ESC or ACC / AHA implant guidelines; - Subjects who are planned to be implanted with all leads intended for a specific device type (dual chamber pacemaker: atrial and right ventricular lead, CRT-P: atrial, right and left ventricular lead) or are already implanted with such leads; - Subjects who receive or are implanted with a bipolar atrial lead. Exclusion Criteria: - Women of childbearing potential who are or might be pregnant at the time of the study (method of assessment upon physician's discretion); - Enrolled in any other concurrent study, with the exception of local mandatory governmental registries and observational studies/registries that are not in conflict or affect - Schedule of procedures for IVORY (i.e. should not cause additional or missed visits); - Programming of devices for IVORY per CIP; - IVORY outcome (i.e. involve medications that could affect the heart rate of the subject); - Conduct of IVORY per GCP / ISO 14 155:2011 / local regulations. - Subjects who live at such a distance from the clinic that travels for FU visits at a study center would be unusually difficult or burdensome for the subject; - Inability or refusal to comply with the FU schedule; - A life expectancy of less than 12 months, per physician discretion; - Subjects who are planned to be programmed to a pacing mode other than DDD / DDDR during the study period. |
Country | Name | City | State |
---|---|---|---|
Austria | Wilhelminenspital | Vienna | |
Austria | Landesklinikum Wiener Neustadt | Wiener Neustadt | |
Belgium | Clinique Universitaires Saint Luc | Brussels | |
Denmark | Rigshospitalet Copenhagen | Copenhagen | |
Denmark | Gentofte University Hospital | Hellerup | |
France | NCN Nouvelles Cliniques Nantaises | Nantes Cedex 2 | |
France | Clinique Saint-Hilaire Rouen | Rouen | |
Germany | Krankenhaus Neu Bethlehem | Göttingen | |
Germany | Heinrich Braun Krankenhaus | Zwickau | |
Hong Kong | Prince of Wales Hospital | Shatin | New Territories |
Italy | Azienda Ospedaliera Mater Domini Policlinico Universitario | Catanzaro | CZ |
Italy | Policlinico Casilino | Roma | RM |
Malaysia | Institut Jantung Negara | Kuala Lumpur | |
Netherlands | Amphia Ziekenhuis | Breda | |
Netherlands | Rijnland Ziekenhuis | Leiderdorp | |
Spain | Hospital Clinico Y Provincial | Barcelona | |
Spain | Clinica Universitaria de Navarra | Pamplona | |
Sweden | Sahlgrenska University Hospital | Göteborg | |
Sweden | Karolinska Hospital | Stockholm | |
United Kingdom | Golden Jubilee National Hospital | Clydebank | |
United Kingdom | Northern General Hospital | Sheffield |
Lead Sponsor | Collaborator |
---|---|
Boston Scientific Corporation |
Austria, Belgium, Denmark, France, Germany, Hong Kong, Italy, Malaysia, Netherlands, Spain, Sweden, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Accuracy of Commanded Right Atrial Automatic Threshold (RAAT) | Accuracy was evaluated by the proportion of tests resulting in an RAAT commanded threshold with |Manual unipolar threshold - commanded threshold| = 0.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for purposes of endpoint analysis. A paired dataset consisted of the manual unipolar threshold and the commanded threshold obtained at a visit. | 3 months post implant | |
Primary | System-related Complication-free Rate | Arms/Groups are only applicable for the outcome measure 'Secondary Outcome: RYTHMIQ - Median Relative Reduction of RV Pacing Percent (RVPP) for RYTHMIQ Programmed to ON vs. RYTHMIQ Programmed to OFF'.
This outcome measure was analyzed only for the combined population and both pacemakers and CRT-P devices were pooled for the analysis. The analysis assesses the system-related complication (SRC) -free rate (excluding LV related events for CRT-P subjects) for subjects implanted or attempted to be implanted with a study device through the first 90 days following the implant procedure. |
90 days post-implant | |
Secondary | Accuracy of Ambulatory RAAT | Arms/Groups are only applicable for the outcome measure 'Secondary Outcome: RYTHMIQ - Median Relative Reduction of RV Pacing Percent (RVPP) for RYTHMIQ Programmed to ON vs. RYTHMIQ Programmed to OFF'.
This outcome measure was analyzed only for the combined population (pacemaker and CRT-P). Accuracy was evaluated by the proportion of tests resulting in an RAAT ambulatory threshold with |ambulatory threshold - commanded threshold| = 1.0V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for purposes of endpoint analysis. A paired dataset consisted consisted of the ambulatory threshold obtained within 7 days prior to the visit and the commanded threshold obtained at the visit. |
3 months post-implant | |
Secondary | Appropriate RAAT Test Outcome | Arms/Groups are only applicable for the outcome measure 'Secondary Outcome: RYTHMIQ - Median Relative Reduction of RV Pacing Percent (RVPP) for RYTHMIQ Programmed to ON vs. RYTHMIQ Programmed to OFF'.
This outcome measure was analyzed only for the combined population (pacemaker and CRT-P). Accuracy was evaluated by the proportion of tests with an appropriate commanded RAAT test outcome. An appropriate RAAT outcome consists of either a device-determined threshold or a code indicating that a threshold could not be determined and representing a condition that is beyond the control of the RAAT feature and could occur as well in manual threshold test, such as atrial fibrillation. |
3 months post-implant | |
Secondary | RYTHMIQ - Median Relative Reduction of RV Pacing Percent (RVPP) for RYTHMIQ On at Pre-Discharge, Off at 1-Month vs. RYTHMIQ Off at Pre-discharge, On at 1-Month | Chronic success is assessed by a median relative reduction of RV pacing percent (RVPP) for RYTHMIQ On at Pre-Discharge, Off at 1-Month vs. RYTHMIQ On at Pre-Discharge, Off at 1-Month. All patients received both RYTHMIQ programmed to ON and programmed to OFF in two consecutive periods, where the patient's programming allocation was randomized for the first period. Then a crossover to the alternate setting occurred for the second period once the end of the first period was reached. | 3 months post implant | |
Secondary | Percentage of RAAT Threshold Tests With Sufficient RAAT Pace Output Margin | This outcome measure was analyzed only for the combined population (Pacemaker and CRT-P). The sufficient pacing output voltage that is able to capture the right atrium was evaluated by the proportion of Right Atrial Automatic Threshold (RAAT) tests with [RAAToutput = (max(BP,UP) + d )] where BP refers to the manual bipolar threshold, UP refers to the manual unipolar threshold, and d refers to the safety margin of 0.5V. Subjects were allowed to contribute multiple paired datasets for this endpoint analysis, one set each from the 1-month and 3-month visits. Paired datasets from the 1-month and 3-month visits were pooled for purposes of endpoint analysis. A paired dataset consisted of the commanded threshold and the maximum manual threshold (i.e. the maximum of the manual unipolar and manual bipolar thresholds) obtained at a visit. | 3 months post implant |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|